Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
Researchers are evaluating Risvutatug rezetecan Ris-Rez, a new medicine targeting specific proteins B7-H3 on cancer cells, in people with relapsed small cell lung cancer SCLC. The study compares Ris-Rez with the standard treatment topotecan to see if Ris-Rez can shrink tumors or make them disappear and if it helps participants live longer. It also examines the safety and side effects of both treatments to better understand their impact. Participants with relapsed SCLC will be randomly assigned to receive either Ris-Rez or topotecan. Both treatments will be administered according to standard protocols, with Ris-Rez provided as a biological therapy and topotecan as a drug treatment. The study is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will be monitored through various assessments including survival time, tumor response, symptom changes, brain progression, and quality of life measures. Safety will be closely tracked through adverse event reports, laboratory tests, heart function evaluations, and immune response monitoring. The main outcome focuses on overall survival, with follow-up extending up to approximately 113 weeks to capture long-term effects and responses.
Actively Recruiting
Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.
Actively Recruiting
This trial evaluates the combination of Navlimetostat BMS-986504, pembrolizumab, and chemotherapy compared to placebo with pembrolizumab and chemotherapy in adults with first-line metastatic non-small cell lung cancer having homozygous MTAP deletion. The study is a randomized, double-blind Phase 23 trial sponsored by Bristol-Myers Squibb, aiming to understand treatment benefits in this specific patient group. Participants must have measurable metastatic NSCLC, no prior systemic therapy for metastatic disease, and meet performance status criteria. Participants receive either Navlimetostat plus pembrolizumab and chemotherapy or placebo plus pembrolizumab and chemotherapy. Chemotherapy may include drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given on specified days at specified doses. Treatment is administered in the first-line metastatic setting, with detailed dosing and combinations determined by study protocols. Randomization assigns participants to one of multiple arms to compare the investigational combination against placebo. Throughout the study, participants are monitored for progression-free survival up to 2 years and 5 years, overall survival up to 5 years, as well as response rates and safety outcomes including adverse events and laboratory abnormalities. Assessments follow RECIST v1.1 criteria with independent and investigator reviews. Safety monitoring includes tracking serious adverse events and treatment-related side effects up to 90 days after treatment ends. The study duration extends to the primary completion date in August 2031, with ongoing evaluations for up to 5 years post-treatment.
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.
Actively Recruiting
Researchers are investigating how digital mobility outcomes can help monitor treatment and disease progression in adults with pulmonary hypertension, specifically precapillary pulmonary hypertension. The study aims to see if walking behavior measured by digital sensors correlates with pulmonary arterial pressure assessed by right heart catheterization. This observational trial is led by Simon Jger and focuses on real-world walking activity in this patient population. Participants will wear a small accelerometer device on their lower back for one week at a time during three separate periods at diagnosis, then at follow-up visits scheduled by their treating clinician between 3 to 6 months and again between 6 to 12 months. The sensor is waterproof and does not provide feedback or display data directly to patients. Follow-up visits are planned according to clinical care, and participants can choose to receive feedback on their sensor data at the studys end. During the study, researchers will assess the correlation between the digital mobility measurements and pulmonary arterial pressures at baseline and follow-ups. They will also describe daily walking behavior, including the number and duration of walking episodes and step counts, and explore links with cardiac function and disease progression. Participants will be monitored over about a year, with safety and ongoing assessment integrated into their regular clinical visits.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Tumor Treating Fields TTFields given with pembrolizumab and platinum-based chemotherapy in patients with advanced non-small cell lung cancer NSCLC that has spread to other parts of the body. This study, called LUNAR-2, compares this combination to pembrolizumab and chemotherapy alone, focusing on overall survival and progression-free survival. It also examines outcomes based on the specific subtype of lung cancer and PD-L1 expression levels. Participants receive either the combination of TTFields delivered by the portable NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy, or pembrolizumab and chemotherapy without TTFields. The NovoTTF-200T device delivers electric fields to disrupt cancer cell division and is used continuously at home. Treatments are given according to a randomized, open-label design. During the study, participants will be monitored regularly with evaluations of survival and disease progression for up to six years. Researchers will track response rates, duration of response, disease control, and adverse events. Assessments include measuring cancer status by standardized criteria. This long-term follow-up helps understand the effects and safety of the treatments over time.
Actively Recruiting
Researchers are collecting detailed data over time on people with advanced non-small cell lung cancer NSCLC who have a specific genetic change called METex14 skipping alterations. This observational disease registry aims to understand how treatments and outcomes evolve for these patients, without changing their usual medical care. It is conducted across multiple countries to gather high-quality, standardized information on this particular lung cancer subgroup. Participants in this registry receive systemic therapy as determined by their doctors in routine clinical practice, without any treatments imposed by the study. Data collection starts when participants join the registry and continues through their treatment and follow-up, until death, loss to follow-up, entry into another clinical trial, or the end of the registry period. The registry does not involve administering any study drugs or interventions. Throughout the study, researchers collect information on participant demographics, clinical features including biomarker data, treatment patterns, and safety. They monitor outcomes such as tumor response using standardized criteria, overall survival, and adverse events. Data collection continues up to nearly five years to capture long-term results, providing valuable insights into real-world treatment effectiveness and patient safety over time.
Actively Recruiting
Long-Term Safety Study of Nivolumab and Other Cancer Therapies in Patients from BMS-Sponsored Trials
Researchers are examining the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This phase 2 study focuses on patients who have previously participated in Bristol-Myers Squibb-sponsored trials involving nivolumab and other cancer treatments. The goal is to monitor safety outcomes over an extended period while patients continue or resume treatment. Participants receive specified doses of nivolumab alone or in combination with other drugs such as ipilimumab, cabozantinib, trametinib, relatlimab, capecitabine, bevacizumab, temozolomide, and others according to their assigned study group. The study includes multiple experimental arms with different drug combinations and dosing schedules, all delivered as drug treatments. Participants continue treatment based on eligibility from their parent studies, including those who are on treatment hold or eligible for rechallenge. Throughout the study, participants undergo regular safety assessments to monitor adverse events, serious adverse events, immune-mediated effects, and any events leading to treatment discontinuation. Monitoring begins from the first day of treatment and continues up to 135 days after treatment ends. Researchers also track incidences of death during this period. The total participation duration spans from enrollment through ongoing treatment and post-treatment safety follow-up, with data collected to evaluate long-term treatment safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.
1-10 of 12
1